Sickle Cell Disease: Targeting Alloantibody formation Reduction; RIsk factors, aNd Genetics

Sickle Cell Disease: Targeting Alloantibody formation Reduction; RIsk factors, aNd Genetics - STARRING

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50758

Enrollment

150

Registered

2017-07-10

Start date

2017-09-20

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle Cell Anemia Sickle Cell Disease

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: Sickle Cell disease patient Need for transfusion No alloantibodies

Exclusion criteria

Exclusion criteria: >25 transfusions Chronic transfusion scheme

Design outcomes

Primary

Measure	Time frame
The following determinants will be studied: Time dependent clinical risk factors and genetic risk factors for alloimmunization in SCD patients.	—

Secondary

Measure	Time frame
Response of the innate and adaptive immune system on a blood transfusion in responders (patients that form allo-antibodies) and non- responders (patients that don*t form allo-antibodies)	—

Countries

Netherlands

Outcome results